Webster Bank N. A. Sells 1,400 Shares of Novo Nordisk A/S (NYSE:NVO)

Webster Bank N. A. trimmed its position in Novo Nordisk A/S (NYSE:NVO) by 21.4% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 5,132 shares of the company’s stock after selling 1,400 shares during the quarter. Webster Bank N. A.’s holdings in Novo Nordisk A/S were worth $262,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of the stock. Tdam USA Inc. increased its position in Novo Nordisk A/S by 1.5% in the 1st quarter. Tdam USA Inc. now owns 14,766 shares of the company’s stock valued at $772,000 after buying an additional 214 shares in the last quarter. EagleClaw Capital Managment LLC increased its position in Novo Nordisk A/S by 0.6% in the 1st quarter. EagleClaw Capital Managment LLC now owns 40,499 shares of the company’s stock valued at $2,122,000 after buying an additional 225 shares in the last quarter. Cardinal Capital Management increased its position in Novo Nordisk A/S by 0.6% in the 1st quarter. Cardinal Capital Management now owns 41,292 shares of the company’s stock valued at $2,159,000 after buying an additional 236 shares in the last quarter. Ballentine Partners LLC increased its holdings in Novo Nordisk A/S by 3.5% during the 1st quarter. Ballentine Partners LLC now owns 7,220 shares of the company’s stock worth $378,000 after purchasing an additional 242 shares in the last quarter. Finally, Enterprise Financial Services Corp increased its holdings in Novo Nordisk A/S by 46.4% during the 1st quarter. Enterprise Financial Services Corp now owns 817 shares of the company’s stock worth $42,000 after purchasing an additional 259 shares in the last quarter. 7.12% of the stock is owned by institutional investors and hedge funds.

A number of analysts have commented on the company. Barclays raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $51.85 price objective for the company in a report on Tuesday, June 11th. Deutsche Bank lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $52.42 price objective for the company. in a report on Thursday, June 20th. Pareto Securities lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Tuesday, April 30th. UBS Group reissued a “buy” rating and set a $355.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, June 19th. Finally, Zacks Investment Research raised Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $50.00 price objective for the company in a report on Monday, July 15th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $111.58.

Shares of NYSE NVO traded up $0.15 during midday trading on Friday, reaching $48.72. The company’s stock had a trading volume of 1,285,362 shares, compared to its average volume of 1,684,996. Novo Nordisk A/S has a 12-month low of $41.23 and a 12-month high of $52.83. The firm has a 50 day moving average price of $49.84. The firm has a market cap of $117.40 billion, a PE ratio of 19.33, a P/E/G ratio of 2.20 and a beta of 0.60. The company has a debt-to-equity ratio of 0.07, a current ratio of 0.96 and a quick ratio of 0.66.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Friday, May 3rd. The company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.04. Novo Nordisk A/S had a return on equity of 78.28% and a net margin of 33.60%. The firm had revenue of $4.46 billion for the quarter, compared to the consensus estimate of $4.35 billion. On average, equities analysts anticipate that Novo Nordisk A/S will post 2.43 EPS for the current fiscal year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Featured Story: What is a Fiduciary?

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.